Standard BioTools 과거 수익 실적

과거 기준 확인 0/6

Standard BioTools의 수입은 연평균 -32.2%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 11.7%의 비율로 증가했습니다. 매출은 연평균 13%의 비율로 증가해 왔습니다.

주요 정보

-32.2%

수익 성장률

-3.2%

EPS 성장률

Life Sciences 산업 성장	21.5%
매출 성장률	13.0%
자기자본 수익률	-26.2%
순이익	-159.5%
최근 수익 업데이트	30 Sep 2023

최근 과거 실적 업데이트

Recent updates

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

Dec 19

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Apr 17

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Apr 02

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Oct 14

수익 및 비용 분석

Standard BioTools 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGM:SLGC 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 23	82	-130	126	0
30 Jun 23	101	-141	150	0
31 Mar 23	95	-139	158	0
31 Dec 22	98	-109	155	0
30 Sep 22	102	-83	146	0
30 Jun 22	80	-92	118	0
31 Mar 22	86	-82	96	0
31 Dec 21	82	-88	78	0
30 Sep 21	87	-73	58	-2
30 Jun 21	81	-39	46	0
31 Mar 21	68	-45	40	0
31 Dec 20	56	-53	37	0
31 Dec 19	32	-57	33	0

양질의 수익: SLGC 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SLGC 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SLGC 은(는) 수익성이 없으며 지난 5년 동안 연간 32.2% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SLGC 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SLGC 은(는) 수익성이 없어 지난 해 수익 성장을 Life Sciences 업계( -4.7% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SLGC 현재 수익성이 없기 때문에 마이너스 자본 수익률( -26.25% )을 갖습니다.

Standard BioTools 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

Consensus estimates of losses per share improve by 10%

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 21% to US$3.93

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Less than half of directors are independent

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

Price target decreased to US$6.50

SomaLogic, Inc. Announces the Full-Scale Global Launch of the SomaLogic Certified Site Program

Consensus forecasts updated

High number of new and inexperienced directors

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

SomaLogic appoints former Foundation Medicine chief as executive chair

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Consensus forecasts updated

SomaLogic Provides Revenue Guidance for the Full Year 2022

Price target decreased to US$7.75

Price target decreased to US$11.50

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

SomaLogic, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SomaLogic, Inc. Announces Resignation of Stephen Quake from the Board of Directors, Effective July 17, 2022

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Price target decreased to US$14.50

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

SomaLogic, Inc., Annual General Meeting, Jun 06, 2022

SomaLogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Independent Director exercised options to buy US$275k worth of stock.

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

Now 24% undervalued after recent price drop

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

SomaLogic, Inc. to Report Q4, 2021 Results on Mar 29, 2022

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic Announces That the Company Will Begin Assaying Samples from the Multi-Ethnic Study of Atherosclerosis (Mesa) Study Beginning in the First Quarter of 2022

Oncohost Ltd. Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy

SomaLogic, Inc. Revises Revenue Guidance for the Year Ended December 31, 2021

High number of new and inexperienced directors

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.55 loss per share

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Director recently bought US$160k worth of stock

No independent directors

수익 및 비용 분석